Axsome Therapeutics Inc (AXSM)
82.57
-1.21
(-1.44%)
USD |
NASDAQ |
Jan 08, 16:00
82.00
-0.57
(-0.69%)
Pre-Market: 09:22
Axsome Therapeutics SG&A Expense (Quarterly): 95.56M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
Repligen Corp | 75.61M |
Pfizer Inc | 3.244B |
Marinus Pharmaceuticals Inc | 12.57M |
NovaBay Pharmaceuticals Inc | 2.65M |
Palatin Technologies Inc | 2.021M |